Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1
作者:Jon H. Come、Timothy J. Senter、Michael P. Clark、John J. Court、Zachary Gale-Day、Wenxin Gu、Elaine Krueger、Jianglin Liang、Mark Morris、Suganthini Nanthakumar、Hardwin O’Dowd、Francois Maltais、Ganesh Iyer、John Andreassi、Christina Boucher、Tony Considine、Cameron S. Moody、William Taylor、Arun K. Mohanty、Yulin Huang、Harmon Zuccola、Joyce Coll、Kenneth C. Bonanno、Kevin J. Gagnon、Lu Gan、Fan Lu、Hong Gao、Ananthisrinivas Chakilam、Juntyma Engtrakul、Bin Song、Dan Crawford、Elisabeth Doyle、Tal Kramer、Bryan Vought、Jonathan Phillips、Raymond Kemper、Martin Sanders、Rebecca Swett、Brinley Furey、Ray Winquist、Mark E. Bunnage、Katrina L. Jackson、Paul S. Charifson、Sanjay S. Magavi
DOI:10.1021/acs.jmedchem.1c00944
日期:2021.12.23
Accumulation of verylongchainfattyacids (VLCFAs) due to defects in ATP binding cassette protein D1 (ABCD1) is thought to underlie the pathologies observed in adrenoleukodystrophy (ALD). Pursuing a substrate reduction approach based on the inhibition of elongation of verylongchainfattyacid 1 enzyme (ELOVL1), we explored a series of thiazole amides that evolved into compound 27─a highly potent
The present invention covers 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds of general formula (I) and general formula (l-a): in which A, R1 and R2 are as defined herein, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, and compounds of general formula (l-c) and general formula (l-d): in which R1 and R2 are as defined herein, for the treatment and/or prophylaxis of diseases, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions.